Guanosine 5'-diphosphate is an endogenous nucleotide ligand that binds guanine nucleotide-dependent proteins, including GTPases and nucleotide-processing enzymes. It is not a standard PROTAC warhead for selective degradation of a single protein target, but it can serve as a biochemical recognition motif in studies involving nucleotide-binding pockets. In a targeted degradation concept, a guanosine diphosphate-derived ligand would require careful validation of target selectivity and a linker-tolerant attachment site that preserves nucleotide recognition. Coupling such a motif to an E3 ligase recruiter could, in principle, test whether nucleotide-binding proteins can be brought into proximity with ubiquitination machinery. This molecule is most useful for enzymology, GTPase biology, nucleotide-binding assay development, affinity probe design, and exploratory ligand discovery rather than routine heterobifunctional PROTAC construction.
Structure of 146-91-8
* For research and manufacturing use only. Not for human or clinical use.
| Size | Price | Stock | Quantity |
|---|---|---|---|
| -- | $-- | In stock |
Looking for different specifications? Click to request a custom quote!
Capabilities & Facilities
Popular Publications Citing BOC Sciences Products
Mechanism of Action: Guanosine 5'-diphosphate is useful for customers studying GTPase-dependent regulation of intracellular trafficking and protein turnover. As a key nucleotide state in GTPase cycling, it can support analysis of autophagy, lysosomal transport, vesicle dynamics, and degradation-linked signaling pathways.
Applications• Nucleotide-Based E3 Recruitment: Guanosine 5'-diphosphate can be used as a functional ligand element in PROTAC designs that aim to engage nucleotide-binding or related recognition pockets on target proteins, enabling proximity-driven ubiquitination. In targeted protein degradation workflows, such moieties may support rational placement of the linker to promote efficient ternary complex formation and subsequent proteasomal turnover.
• Proximity-Driven Degradation Studies: This nucleotide scaffold may be incorporated into PROTAC constructs to systematically test how binding orientation and linker geometry influence formation of an E3 ligase–target–PROTAC ternary complex. Researchers can evaluate degradation kinetics, dose–response behavior, and dependence on ubiquitination machinery to determine whether Guanosine 5'-diphosphate–anchored binding enhances selective depletion.
• Biochemical Mechanism Probing: Guanosine 5'-diphosphate–based PROTACs can be applied to dissect degradation mechanisms in nucleotide-regulated protein systems. By comparing degradation outcomes across mutants that alter nucleotide binding or conformational states, investigators can infer whether ternary complex stability and receptor engagement are the dominant determinants of ubiquitin-mediated clearance.
• Structure-Guided PROTAC Optimization: The diphosphate functionality offers handles for designing linker attachment strategies that preserve key electrostatic interactions while tuning spatial reach. In PROTAC optimization, researchers can use structure-guided modeling and iterative synthesis to refine binding affinity, ternary complex residence, and degradation potency, targeting improved selectivity over closely related nucleotide-binding proteins.
Structure: The structure of Guanosine 5'-diphosphate is characterized by primary or secondary amine/basic nitrogen centers; phenol or alcohol functionality. These features provide defined hydrogen-bonding, hydrophobic, and steric elements that can support affinity retention while enabling analogue-based linker-vector selection.
Reactivity: The amine/basic nitrogen-containing motif can be evaluated for acylation, sulfonylation, alkylation, or carbamate/urea linker installation when that vector is solvent exposed. For PROTAC construction, the POI ligand can be paired with CRBN ligands such as thalidomide, pomalidomide, or lenalidomide analogues, VHL ligands such as VH032 derivatives, or less common IAP/MDM2/cIAP-recruiting ligands, with alkyl, PEG, piperazine, triazole, or amide linkers screened for ternary-complex formation. In practice, incorporation into PROTACs should begin from derivatives that preserve the reported binding pharmacophore, followed by systematic variation of linker length, polarity, rigidity, and exit-vector geometry to optimize target engagement, E3 recruitment, and cellular degradation readouts.
* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2
Please contact us with any specific requirements and we will get back to you as soon as possible.